menu toggle

FormularyDecisions Connection Newsletter

Browse new features, discover platform releases, learn about upcoming events, and stay up to date on all the latest insights.

In this month's newsletter ..

  • Prepare for the upcoming RSV and flu season with information on vaccines 
  • Check out an upcoming ThoughtSpot 2024 session titled“ Old bugs, new tricks: the latest on vaccines, immunization schedules, and community health“ 
  • You asked, we listened: the enhanced eRequest is here 
  • Peruse the latest Resource Center files  
  • Missed the webinar? Watch the recording of “Bracing for the impact of biosimilars: Navigating terrain in the U.S. market landscape”
  • Celebrate managed care pharmacy professionals 
 

Explore insights on vaccines and immunization trends

SPS-abstract2
According to the World Health Organization, available vaccines prevent 3.5-5 million deaths every year from more than 20 life-threatening diseases, including diphtheria, tetanus, pertussis, influenza, and measles.1 Prepare for the upcoming RSV and flu season with information on vaccines on FormularyDecisions.

For a repository of clinical guideline recommendations, explore Clinical Guideline Snapshots that mention vaccines including respiratory syncytial virus and COVID-19 prevention. Created by clinical experts from The Medical Letter, Clinical Guideline Snapshots summarize key information from published clinical guidelines and highlight the most recent updates.

newsletter

 

Leverage the Metasearch Results across different vaccine disease and product pages where you can find a number of articles from credible resources and publications such as PubMed, Journal of Managed Care & Specialty Pharmacy, Pharmacist’s Letter, and more.

While the Metasearch Results provides an extensive catalog of articles, here is a sample list of articles available across different vaccine disease and product pages:

 

Attending ThoughtSpot?

abstract

 

If you or your colleagues are planning on attending ThoughtSpot 2024 in Orlando, Florida this month, be sure to check out the following session on vaccines that will be presented by Cencora’s Nick Howard, PharmD, Health Outcomes & Market Access Fellow and Tasmina Hydery, PharmD, MBA, BCGP, Associate Director of Digital Solutions.

Session: Old bugs, new tricks: the latest on vaccines, immunization schedules, and community health
Date: Thursday, July 25, 2024
Time: 4-5 pm ET

Each year, the healthcare system grapples with increased infections and hospitalizations that disproportionately affect vulnerable populations such as infants and adults over the age of 60. In light of the introduction of new preventive measures and vaccines, pharmacy professionals need to be equipped with background on their approved indications, clinical trial results, recent clinical guideline recommendations, and considerations for use. New evidence, including real-world data, can also signify methods and strategies for the implementation of vaccines in the evolving clinical landscape. 

In this session, we will explore the key differences between newly approved agents, their place in therapy based on 2024 immunization recommendations, and best practices for discussing vaccines in diverse community pharmacy settings. Given that vaccination rates can be affected by many factors, including cultural, social, and political influences, the session will incorporate interactive case studies to also address opportunities for overcoming vaccine fatigue and hesitancy.   

Pharmacist Learning Objectives: 

1. Summarize the clinical trial results and considerations for use of newly approved agents.  
2. Review 2024 immunization schedules and recommendations based on expert consensus guidelines. 
3. Review guidance for administration of vaccines. 
4. Apply strategies for discussing vaccines with patients in the pharmacy setting to improve overall community health outcomes.

Pharmacy Technician Learning Objectives:

1. Review guidance for administration of vaccines. 
2. Apply strategies for discussing vaccines with patients in the pharmacy setting to improve overall community health outcomes.

 

 

You asked, we listened:

The enhanced eRequest is here!

As a core feature on FormularyDecisions for over a decade, the eRequest streamlines your process of requesting product information from numerous biopharma Medical Information departments. Easily accessible throughout FormularyDecisions including the Homepage and individual Product pages, the eRequest now provides increased transparency, clarity, and efficiency in your search for product information. 

eRequest

Log into FormularyDecisions today to leverage the following latest enhancements to the eRequest:

  • eDossier availability status: Instantly identify whether products have eDossiers available on FormularyDecisions with our new color-coded product dropdown. This transparency ensures that you have immediate visibility into the availability status of eDossiers and distinguishes between those that are accessible upon approval or require a response from the biopharma company.
  • Disease state of interest field: Not only will this new field match you with the disease state-specific eDossier you are searching for, but it will also prompt FormularyDecisions to recommend other product eDossiers you may find relevant. 
  • Distinct option for “Other Information” requests: In addition to requesting eDossiers, you now have a separate option to request “Other information.” This distinction allows you to clearly ask for any clinical and economic product information including product briefs, clinical overviews, publications, posters, and more!
 

Explore the latest Resource Center files

Several biopharma companies recently posted new or updated content in their Resource Centers, including product briefs, clinical overviews, publications, posters, and more! Many of these resources contain consolidated, up-to-date product information that you can include in your upcoming product reviews. See below for Resource Center files posted in the last 3 months.

Click here to view a list of all products with Resource Center files.
FDA-approved product namea
Resource Center document description(s)

APRETUDE (cabotegravir extended-release injectable suspension)2

Head-to-head trials and cost-effectiveness analysis

BREZTRI AEROSPHERE® (budesonide, glycopyrrolate, and formoterol fumarate)3

Clinical value profile

CABENUVA (cabotegravir and rilpivirine)4

Clinical data summary and real-world adherence and persistence summary

HEMGENIX® (etranacogene dezaparvovec-drlb)5

3-year data report, reimbursement guide, P&T summary, and product information in AHFS format

IMBRUVICA® (ibrutinib)6

Dose modification guide and treatment resistance resources

JOENJA® (leniolisib)7

Open-label extension study

KERENDIA® (finerenone)8

Population Health Management article, assessment of UACR change and clinical outcomes, and assessment of UACR change and economic outcomes

KEVZARA® (sarilumab)9

Clinical trials and disease overview resources

MAVYRET® (glecaprevir and pibrentasvir)10

Drug class review table

NEXLIZET® (bempedoic acid and ezetimibe)11

Budget impact model and the link to the NEJM CLEAR Outcomes publication

NUBEQA® (darolutamide)12

RWE and disease stage-based cost analysis

OGSIVEO™ (nirogacestat)13

Clinical overview, ICD-10 codes, limited distribution network information, EHR order set clinical instructions, link to NEJM article

RINVOQ® (upadacitinib)14

Network meta-analysis

RUKOBIA™ (fostemsavir)15

Clinical value

SAPHNELO® (anifrolumab-fnia)16

Clinical value, dosing and administration guide, long-term extension safety study, limited distribution information, access and reimbursement guide, and coding and billing guides

VOWST™ (fecal microbiota spores, live-brpk)17

A phase 3, double-blind, randomized, placebo-controlled trial in NEJM and a phase 3, open-label, single-arm trial in JAMA


Key: AHFS – American Hospital Formulary Service; CLEAR – Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen; EHR – electronic health record; ICD-10 – International Classification of Diseases 10th Revision; JAMA – Journal of the American Medical Association; NEJM – The New England Journal of Medicine; P&T – Pharmacy & Therapeutics; RWE – real-world evidence; UACR – urine albumin-to-creatinine ratio.

 

Pre-approval product nameb
Resource Center document description(s)

CSL-312 (garadacimab)

PIE presentation

Mirdametinib (PD-0325901)

PIE presentation and patient vignette

mRESVIA (mRNA-1345)

PIE presentation


Key: PIE – pre-approval information exchange

 


 

 

Webinar(s)

Webinar recording available!

Academy of Managed Care Pharmacy (AMCP) Webinar hosted by FormularyDecisions

Session: Bracing for the Impact of Biosimilars: Navigating Terrain in the US Market Landscape 
Recorded on: June 11, 2024 

Watch this interactive, engaging, and informative discussion to discover the keys to thriving in the dynamic biosimilars landscape. In this session, you will gain practical insights on navigating regulatory challenges, seizing opportunities for collaboration, and communicating effectively with stakeholders. Stay ahead of the curve with up-to-date industry trends and expert strategies tailored to driving success in the U.S. biosimilars market. 

Learning objectives: 

  • Review the US biosimilars market landscape and the current legislative and regulatory environment. 
  • Identify key factors affecting payer uptake and provider adoption of biosimilars in the US 
  • Explore challenges and opportunities associated with biosimilars for stakeholders across the healthcare continuum. 
  • Position yourself for success by leveraging expert strategies and insights to proactively address potential market challenges. 
 

Celebrating Managed Care Pharmacy Professionals — #WeAreMCPs


Like you, the FormularyDecisions team is made up of managed care professionals (MCPs) who are driven to make an impact on patient lives by connecting you with information on more than 3,700 pipeline and FDA-approved products. We invite you to connect with us at an upcoming conference or schedule a virtual meeting to add us to your expanding network of professionals. Schedule a meeting today!
newsletter
Filter from wearemcps.amcp.org

“My MCP superpower is as a master connector. I love networking with other MCPs and providing solutions for how we search for and share data, evidence, and insights. Whether in industry, a managed care organization, health system, consultancy, or technology, we all have the same mission of improving care for the patients we serve. Bonding over treats like bubble tea is always a bonus. Looking forward to meeting you and other fellow MCPs at a future conference!” – Cynthia Thai, PharmD
FormularyDecisions-body1-504x504

 

Share with your peers

Know someone who could benefit from access to information on over 3,000 pipeline and FDA-approved products? Take a few seconds and use our email template to inform your peers or colleagues about FormularyDecisions.
Man working on a laptop computer

Learn something new

Equip your clinical team with a resource that streamlines the search for relevant product information. Schedule a demo and ensure your team is leveraging all that FormularyDecisions has to offer.

 

Questions?

We welcome your questions and feedback! Please reach out to the FormularyDecisions team today.
 
References:
1. World Health Organization. Vaccines and immunization: overview. https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1 
2. Apretude prescribing information. Viiv Healthcare; 2023. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Apretude/pdf/APRETUDE-PI-PIL-IFU.PDF 
3. Breztri aerosphere prescribing information. AstraZeneca Pharmaceuticals LP; 2022. http://www.azpicentral.com/pi.html?product=breztri 
4. Cabenuva prescribing information. Viiv Healthcare; 2023. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF 
5. Hemgenix prescribing information. CSL Behring LLC; 2022. https://labeling.cslbehring.com/PI/US/Hemgenix/EN/Hemgenix-Prescribing-Information.pdf 
6. Imbruvica prescribing information. AbbVie Inc.; 2024. https://www.rxabbvie.com/pdf/imbruvica_pi.pdf 
7. Joenja prescribing information. Pharming Healthcare Inc.; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217759s000lbl.pdf 
8. Kerendia prescribing information. Bayer HealthCare Pharmaceuticals; 2022. https://labeling.bayerhealthcare.com/html/products/pi/Kerendia_PI.pdf 
9. Kevzara prescribing information. sanofi-aventis; 2024. https://products.sanofi.us/kevzara/kevzara.pdf 
10. Mavyret prescribing information. AbbVie Inc.; 2023. https://www.rxabbvie.com/pdf/mavyret_pi.pdf 
11. Nexlizet prescribing information. Esperion Therapeutics; 2024. https://pi.esperion.com/nexlizet/nexlizet-pi.pdf 
12. Nubeqa prescribing information. Bayer HealthCare Pharmaceuticals; 2023. https://labeling.bayerhealthcare.com/html/products/pi/Nubeqa_PI.pdf?inline=- 
13. Ogsiveo prescribing information. SpringWorks Therapeutics, Inc.; 2024. https://springworkstx.com/wp-content/uploads/2024/04/OGSIVEO-US-Prescribing-Information-04.04.24.pdf 
14. Rinvoq prescribing information. AbbVie Inc.; 2024. https://www.rxabbvie.com/pdf/rinvoq_pi.pdf 
15. Rukobia prescribing information. ViiV Healthcare; 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212950s004lbl.pdf 
16. Saphnelo prescribing information. AstraZeneca LLP; 2024. https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/44b6985c-8268-46b1-ba3e-2bb43bfd4d4c/44b6985c-8268-46b1-ba3e-2bb43bfd4d4c_viewable_rendition__v.pdf 
17. Vowst prescribing information. Nestlé Health Science; 2023. https://www.serestherapeutics.com/our-products/VOWST_PI.pdf 
 

The material is being shared to inform you of the availability of information on FormularyDecisions. In providing this information, FormularyDecisions is not promoting any products mentioned, making claims about risks or benefits, or otherwise recommending any product in general or for any patient or formulary. For complete information about the indications, risks, and benefits of any product, please consult appropriate clinical and safety information, including the complete product label and important safety information. All prescribing decisions and/or coverage decisions should be made independently by individuals with appropriate experience in reliance on their independent judgement. 

b The products listed are in the clinical evaluation stage and have not been approved for use by the FDA. The safety and efficacy of these products have not been established. FormularyDecisions is providing this information to alert you to the status of this product and is not promoting this product generally or otherwise recommending this product for use in the treatment of any disease or inclusion on any formulary for which it has not yet been approved.
 
FormularyDecisions is owned and operated by Xcenda L.L.C., which is a subsidiary of Cencora, a global pharmaceutical sourcing and distribution services company.
 
The contents of this communication are non-promotional and intended exclusively for healthcare decision makers, formulary committees, and other similar entities responsible for selecting healthcare products for coverage or reimbursement. FormularyDecisions strongly encourages our members to review all available information about a particular product, including but not limited to the product label, and to rely on their experience and expertise in making decisions about coverage or prescribing.